If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
111.00    1.50 (1.37%)
Bid:
110.00
Ask:
112.00
Spread: 2.00 (1.818%)
Market Cap: £14.97m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Awards under Long Term Incentive Plan

10 Jan 2013 07:01

RNS Number : 2205V
Revolymer PLC
10 January 2013
 



10th January 2013

Revolymer plc

("Revolymer" or "the Group")

Awards under Long Term Incentive Plan

 

Revolymer (AIM: REVO), the British polymer company developing patented products for a number of high value fast moving consumer goods ("FMCG") and industrial markets, announces the grant on 9 January 2013 of awards under the Revolymer plc Long Term Incentive Plan ("LTIP") to executive directors.

 

The LTIP was adopted by the board of directors of Revolymer plc (the "Board") on 29 June 2012 and its remuneration committee has approved the following grants to executive directors on 9 January 2013:

 

- To the CEO Roger Pettman a nil cost option over 281,690 ordinary shares

- To the CFO Robin Cridland a nil cost option over 253,521 ordinary shares

 

The vesting period of these grants is three years and they only become exercisable if challenging performance conditions are met; namely that 50% of the grant becomes exercisable if the weighted average ordinary share price in the 30 day period ending on the third anniversary of grant is 125p. Between weighted average ordinary share prices of 125p and 150p, vesting shall be pro-rata and on a straight line basis between 50% and 100%. Below 125p the grants are not exercisable and lapse in full.

The Board also requires the executive directors to maintain minimum interests (of at least 400,000 ordinary shares for Roger Pettman and 360,000 ordinary shares for Robin Cridland) before selling any ordinary shares that are the result of exercise, except that they may sell that number of ordinary shares that are required to satisfy any income tax and employee's national insurance liabilities arising at exercise. This requirement shall not apply on a change of control, or other transaction with substantially the same effect.

Ends

 

For further information please contact:

 

Revolymer plc

+44 (0) 1244 283 500

Roger Pettman

Rob Cridland

Panmure Gordon (UK) Limited

+44 (0) 20 7886 2500

Callum Stewart / Adam James (Corporate Finance)

Adam Pollock / Charles Leigh-Pemberton (Corporate Broking)

Citigate Dewe Rogerson

+44 (0)20 7638 9571

Simon Rigby / David Dible / Ginny Pulbrook

 

 

 

About Revolymer

Revolymer is a technology company that designs, develops and formulates novel polymers to improve the performance of existing consumer products within the FMCG markets. Revolymer's strategy is to generate significant and growing revenue streams by licensing its unique and proprietary technologies to manufacturers and marketers within the global high value FMCG industry. Current applications for the Group's technologies are in the coatings & adhesives, household products and personal care markets (together "Consumer Specialties") and the confectionery chewing gum and medicated chewing gum (together "Gum") markets.

 

www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBLMTTMBBMTTJ
Date   Source Headline
15th May 20151:17 pmRNSHolding(s) in Company
11th May 20157:05 amRNSDirector Declaration
5th May 20157:01 amRNSDirector/PDMR Shareholding
13th Apr 20157:00 amRNSNotice of AGM
30th Mar 20157:00 amRNSPreliminary Results
24th Mar 20157:15 amRNSDirector Declaration
9th Jan 20157:00 amRNSBlocklisting Interim Review
5th Jan 201512:00 pmRNSTotal Voting Rights
11th Dec 20147:00 amRNSHolding(s) in Company
10th Nov 20147:00 amRNSPatent Infringement Settled and Discontinued
10th Oct 20144:22 pmRNSTotal Voting Rights
29th Sep 20147:00 amRNSInterim Results
25th Sep 20147:00 amRNSGlobal licence signed with Solvay
26th Aug 20147:00 amRNSNew CEO start date confirmed
9th Jul 20147:00 amRNSBlocklisting Interim Review
4th Jul 20147:00 amRNSAppointment of Chief Executive Officer
2nd Jul 20147:00 amRNSTotal Voting Rights
23rd Jun 20147:01 amRNSNotification of Major Interest in Shares
23rd Jun 20147:00 amRNSNotification of Major Interest in Shares
9th Jun 20147:00 amRNSUS supply agreement for nicotine chewing gum
3rd Jun 20147:00 amRNSTotal Voting Rights
22nd May 201412:34 pmRNSResult of AGM
30th Apr 20143:16 pmRNSNotification of Major Interest in Shares
24th Apr 20147:00 amRNSAward under Long Term Incentive Plan
23rd Apr 201412:45 pmRNSNotification of Major Interest in Shares
23rd Apr 20147:00 amRNSNotice of AGM
22nd Apr 201411:58 amRNSTotal Voting Rights
14th Apr 20147:00 amRNSAward of Technology Strategy Board funding
31st Mar 20147:00 amRNSPreliminary Results
3rd Mar 20147:00 amRNSTotal Voting Rights
30th Jan 201411:39 amRNSBlock Listing
27th Jan 20147:00 amRNSDirectorate Change
24th Jan 20144:46 pmRNSHolding(s) in Company
10th Jan 20147:00 amRNSBlock Listing Six Monthly Return
20th Nov 20137:00 amRNSMarketing approval of nicotine gum in Europe
17th Oct 20137:00 amRNSSupply and Distribution Agreement with Amma Polska
11th Oct 20137:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
25th Sep 20137:00 amRNSInterim Results
1st Aug 20137:00 amRNSTotal Voting Rights
22nd Jul 20137:00 amRNSAward of contract to supply nicotine gum
15th Jul 201312:20 pmRNSChange of Registered Office
9th Jul 20137:00 amRNSBlocklisting Interim Review
28th May 20132:02 pmRNSResult of AGM
17th Apr 20134:47 pmRNSHolding(s) in Company
17th Apr 20137:00 amRNSDirector's Dealings
9th Apr 20137:00 amRNSPositive test results for encapsulation technology
22nd Mar 20137:00 amRNSNotice of AGM and Posting of Annual Report
13th Mar 20137:00 amRNSPreliminary Results
1st Mar 20137:00 amRNSTotal Voting Rights
1st Feb 20132:42 pmRNSNotice of patent infringement proceedings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.